Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

This study is testing a CAR T cell therapy called Senl-T7, which uses specially engineered immune cells designed to attack a protein called CD7 found on certain leukemia and lymphoma cells. It is for people with relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) — aggressive blood cancers that have not responded to prior treatment. **You may be eligible if...** - You are between 2 and 70 years old - You have T-ALL or T-LBL that has relapsed or did not achieve complete remission after initial treatment - Your cancer cells express the CD7 protein - Your expected survival is more than 12 weeks - Your organ function (liver, blood counts, oxygen levels) meets the required minimums **You may NOT be eligible if...** - You have active, severe heart problems (heart attack in the past year, heart failure, or dangerous arrhythmias) - You have active graft-versus-host disease (GVHD) from a prior transplant - You have active hepatitis B or C, or HIV - You have another advanced, spreading cancer - You have severe, uncontrolled infection - You have a serious autoimmune or immune deficiency condition Talk to your doctor to see if this trial is right for you.